This review aims to summarise the evidence supporting the use of MFS as a clinical endpoint and the benefit of delaying metastasis in men with high-risk nmCRPC, and to discuss the influence of next-generation imaging on prostate cancer staging.
In this issue
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given